Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8713)
All Articles published online
|
Publishing Process of This Article
|
Nov 14, 2015 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol 2015; 21(42): 12101-12113 [PMID: 26576095 DOI: 10.3748/wjg.v21.i42.12101] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v21/i42/12101.htm |
| Number | Citing Articles |
| 1 |
Anand Bhushan, Sumona Ghosh, Samsiddhi Bhattacharjee, Sreedhar Chinnaswamy. Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection. Journal of Interferon & Cytokine Research 2017; 37(8): 369 doi: 10.1089/jir.2017.0002
|
| 2 |
Stuart C. Gordon, Sheri Trudeau, Jia Li, Yueren Zhou, Loralee B. Rupp, Scott D. Holmberg, Anne C. Moorman, Philip R. Spradling, Eyasu H. Teshale, Joseph A. Boscarino, Yihe G. Daida, Mark A. Schmidt, Mei Lu. Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United States. Journal of Clinical Gastroenterology 2019; 53(1): 40 doi: 10.1097/MCG.0000000000000872
|
| 3 |
Figen Sarıgul, Murat Sayan, Ulku User, Nefise Oztoprak. Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict Rules. Hepatitis Monthly 2019; (In Press) doi: 10.5812/hepatmon.62390
|
| 4 |
E. Gane, R. Nahass, V. Luketic, E. Asante‐Appiah, P. Hwang, M. Robertson, J. Wahl, E. Barr, B. Haber. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment‐naïve, noncirrhotic HCV genotype 3‐infected patients. Journal of Viral Hepatitis 2017; 24(10): 895 doi: 10.1111/jvh.12719
|
| 5 |
Zayar Phyo, Ko Ko, Serge Ouoba, Aya Sugiyama, Ulugbek Khudayberdievich Mirzaev, Golda Ataa Akuffo, Chanroth Chhoung, Tomoyuki Akita, Junko Tanaka, Yury E. Khudyakov. Intermediate hepatitis C virus (HCV) endemicity and its genotype distribution in Myanmar: A systematic review and meta-analysis. PLOS ONE 2024; 19(9): e0307872 doi: 10.1371/journal.pone.0307872
|
| 6 |
Maia Butsashvili, Lia Gvinjilia, George Kamkamidze, David Metreveli, Shorena Dvali, Tamar Rukhadze, Amiran Gamkrelidze, Muazzam Nasrullah, Shaun Shadaker, Juliette Morgan, Francisco Averhoff. High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia. BMC Research Notes 2020; 13(1) doi: 10.1186/s13104-020-05173-4
|
| 7 |
Xi Ran, HuaiYi Xie, Wei Li. Sustained Virologic Response Rates of Sofosbuvir and Velpatasvir in Patients with Hepatitis C Genotype 3: A Meta-Analysis. Hepatitis Monthly 2020; 20(1) doi: 10.5812/hepatmon.98798
|
| 8 |
Mariana Sandoval Lourenço, Patricia Momoyo Y Zitelli, Marlone Cunha-Silva, Arthur Ivan N Oliveira, Cláudia P Oliveira, Tiago Sevá-Pereira, Flair José Carrilho, Mario G Pessoa, Daniel F Mazo. Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil. World Journal of Hepatology 2022; 14(1): 195-208 doi: 10.4254/wjh.v14.i1.195
|
| 9 |
Qunying Han, Xiude Fan, Xiaoyun Wang, Ye Wang, Huan Deng, Xiaoge Zhang, Kun Zhang, Na Li, Zhengwen Liu. High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting. Virology Journal 2019; 16(1) doi: 10.1186/s12985-019-1184-y
|
| 10 |
Hilla Knobler, Stephen Malnick. Hepatitis C and insulin action: An intimate relationship. World Journal of Hepatology 2016; 8(2): 131-138 doi: 10.4254/wjh.v8.i2.131
|
| 11 |
Jia‐Horng Kao, Sang Hoon Ahn, Rong‐Nan Chien, Mong Cho, Wan‐Long Chuang, Sook‐Hyang Jeong, Chen‐Hua Liu, Seung‐Woon Paik. Urgency to treat patients with chronic hepatitis C in Asia. Journal of Gastroenterology and Hepatology 2017; 32(5): 966 doi: 10.1111/jgh.13709
|
| 12 |
Jyoti Gupta, Minnah Irfan, Niranjan Ramgir, K. P. Muthe, A. K. Debnath, Shabnam Ansari, Jaya Gandhi, C. T. Ranjith-Kumar, Milan Surjit. Antiviral Activity of Zinc Oxide Nanoparticles and Tetrapods Against the Hepatitis E and Hepatitis C Viruses. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.881595
|
| 13 |
Mai H. A. Mousa, Nermin S. Ahmed, Kai Schwedtmann, Efseveia Frakolaki, Niki Vassilaki, Grigoris Zoidis, Jan J. Weigand, Ashraf H. Abadi. Design and Synthesis of Novel Symmetric Fluorene-2,7-Diamine Derivatives as Potent Hepatitis C Virus Inhibitors. Pharmaceuticals 2021; 14(4): 292 doi: 10.3390/ph14040292
|
| 14 |
Abhilasha Madhvi, Smita Hingane, Rajpal Srivastav, Nishant Joshi, Chandru Subramani, Rajagopalan Muthumohan, Renu Khasa, Shweta Varshney, Manjula Kalia, Sudhanshu Vrati, Milan Surjit, C. T. Ranjith-Kumar. A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-04449-3
|
| 15 |
Yilihamu Abulitifu, Jiangshan Lian, Munire Adilijiang, Lan Liu, Fengcong Zhao, Wen Qian, Yongping Zhang. Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China. Infection and Drug Resistance 2022; : 6463 doi: 10.2147/IDR.S385071
|
| 16 |
Steven W. Johnson, Dorothea K. Thompson, Brianne Raccor. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Current Infectious Disease Reports 2017; 19(6) doi: 10.1007/s11908-017-0578-5
|
| 17 |
Nikolaos Lougiakis, Efseveia Frakolaki, Panagiota Karmou, Nicole Pouli, Panagiotis Marakos, Vanesa Madan, Ralf Bartenschlager, Niki Vassilaki. Novel nucleoside analogues targeting HCV replication through an NS5A‐dependent inhibition mechanism. Chemical Biology & Drug Design 2017; 90(3): 352 doi: 10.1111/cbdd.12966
|
| 18 |
Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. Hepatology International 2019; 13(2): 173 doi: 10.1007/s12072-019-09927-6
|
| 19 |
Vasiliki Pardali, Erofili Giannakopoulou, George Mpekoulis, Vassilina Tsopela, Georgios Panos, Martin C. Taylor, John M. Kelly, Niki Vassilaki, Grigoris Zoidis. Novel Lipophilic Hydroxamates Based on Spirocarbocyclic Hydantoin Scaffolds with Potent Antiviral and Trypanocidal Activity. Pharmaceuticals 2023; 16(7): 1046 doi: 10.3390/ph16071046
|